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Objective: We previously showed that arrest with multidose infusions of high-dose
(1 mmol/L) esmolol (an ultra-short-acting -blocker) in oxygenated Krebs-Hense-
leit buffer (esmolol cardioplegia) provided complete myocardial protection after 40
minutes of normothermic (37°C) global ischemia in isolated rat hearts. In this study
we investigated the importance of oxygenation for protection with esmolol cardio-
plegia, compared it with that of St Thomas’ Hospital cardioplegia, and determined
the protective efficacy of multidose esmolol cardioplegia for extended ischemic
durations.
Methods: Isolated rat hearts (n  6/group) were perfused in the Langendorff mode
at constant pressure (75 mm Hg) with oxygenated Krebs-Henseleit bicarbonate
buffer at 37°C. The first part of the first study had four groups: (i) multidose (every
15 minutes) oxygenated (95% oxygen/5% carbon dioxide) Krebs-Henseleit buffer
during 60 minutes of global ischemia, (ii) multidose deoxygenated (95% nitro-
gen/5% carbon dioxide) Krebs-Henseleit buffer during 60 minutes of global ische-
mia, (iii) multidose oxygenated esmolol cardioplegia during 60 minutes of global
ischemia, and (iv) multidose deoxygenated esmolol cardioplegia during 60 minutes
of global ischemia. The second part of the first study had three groups: (v) multidose
St Thomas’ Hospital solution during 60 minutes of global ischemia, (vi) multidose
oxygenated St Thomas’ Hospital solution during 60 minutes of global ischemia, and
(vii) multidose oxygenated esmolol cardioplegia during 60 minutes of global ische-
mia. In the second study, hearts were randomly assigned to 60, 75, 90, or 120
minutes of global ischemia and at each ischemic duration were subjected to
multidose oxygenated constant flow or constant pressure infusion of (i) Krebs-
Henseleit buffer (constant flow), (ii) Krebs-Henseleit buffer (constant pressure), (iii)
esmolol cardioplegia (constant flow), or (iv) esmolol cardioplegia (constant pres-
sure). All hearts were reperfused for 60 minutes, and recovery of function was
measured.
Results: Multidose infusion of oxygenated esmolol cardioplegia completely pro-
tected the hearts (97%  5%) after 60 minutes of 37°C global ischemia. Deoxy-
genated esmolol cardioplegia was significantly less protective (45%  8%). Oxy-
genation of St Thomas’ Hospital solution did not alter its protective efficacy in this
study (70%  4% vs 69%  7%). Infusion of esmolol cardioplegia at constant
pressure provided complete protection for 60, 75, and 90 minutes (104%  5%,
95%  5%, and 95%  3%, respectively), whereas protection with constant-flow
esmolol cardioplegic infusion was significantly decreased at ischemic durations
longer than 60 minutes. This decrease in efficacy of constant-flow esmolol cardio-
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plegia was associated with increasing coronary perfusion pressure leading to myo-
cardial injury.
Conclusions: Oxygenation of esmolol cardioplegia (Krebs-Henseleit buffer plus 1.0
mmol/L esmolol) was essential for optimal myocardial protection. Multidose infu-
sion of oxygenated esmolol cardioplegia provided good myocardial protection
during extended periods of normothermic ischemia. Esmolol cardioplegia may
provide an efficacious alternative to hyperkalemia.
Numerous experimental and clinical studieshave demonstrated that -adrenergic an-tagonists (-blockers) can attenuate theextent of myocardial injury during ische-mia and reperfusion,1-4 although themechanism of the cardioprotective effi-
cacy of these drugs during myocardial ischemia is not
completely understood. Possible mechanisms include de-
creasing heart rate and contractility (with a reduction of
myocardial oxygen consumption),5 decreasing sympathetic
tone,6 altering myocardial substrate use,7 stabilizing cell
membranes,8 and reducing lipid peroxidation of membrane
phospholipids.9 The utility of -blockers, however, is lim-
ited by their negative inotropic and chronotropic properties,
and life-threatening adverse effects related to prolonged
-blockade (eg, shock, bradycardia, bronchospasm, pulmo-
nary edema, and complete heart block) remain a clinical
problem.
To minimize the risks of adverse effects related to pro-
longed -blockade therapy in the critically ill patient, a
novel group of ultra–short-acting, titratable -blockers were
designed.10,11 Esmolol, the first such intravenous -blocker,
was developed to produce rapid and titratable -adrenergic
blockade with minimal adverse effects. Esmolol is an ultra–
short-acting, cardioselective -blocker that is rapidly hydro-
lyzed by an esterase in blood cell cytosol12 to form metha-
nol and an acid metabolite (ASL-8123) that is essentially
inactive as a -blocker.13 Esmolol has also been shown to
protect the heart during cardiac surgery; Sweeney and Fra-
zier14 were the first to use esmolol in patients with compro-
mised left ventricular function. High doses of esmolol were
intravenously infused during continuous perfusion of the
coronary arteries with normothermic blood to suppress car-
diac inotropy and chronotropy, such that the heart rate was
slowed sufficiently (without inducing cardiac arrest) to per-
form the operation. Since then, experimental and clinical
studies15-17 have shown that the induction by high-dose
esmolol of adequate cardiac surgical conditions has pro-
vided myocardial preservation equivalent to or better than
cold crystalloid or blood cardioplegia. With this technique,
however, which consists of continuous coronary infusion of
blood containing esmolol, the surgeon is not provided with
a still and blood-free operating field. There have been a few
case reports from surgeons18,19 noting that high-dose esmo-
lol can arrest the heart when the aorta is calcified and that
aortic crossclamping should be avoided.
Previously, we20 showed that multidose infusion of es-
molol cardioplegia in oxygenated buffer completely pro-
tected the myocardium during 40 minutes of normothermic
(37°C) global ischemia in an isolated rat heart preparation.
Moreover, we20 demonstrated that continuous infusion of
esmolol cardioplegia (inducing cardiac arrest) failed to
completely protect myocardial function, despite avoidance
of ischemia, and was significantly less protective than mul-
tidose infusion of esmolol cardioplegia during global ische-
mia. This study was therefore conducted to investigate the
importance of oxygenation in the protective effect of mul-
tidose esmolol cardioplegia; in addition, we examined the
efficacy of multidose esmolol cardioplegic infusions during
prolonged ischemia and sought to determine whether the
method of infusion influenced this protection.
Material and Methods
Animals
Adult male Wistar rats (240-300 g body weight; Bantin and
Kingman, Hull, UK) were used. All animals received humane care
in accordance with the “Guidance on the Operation of the Animals
(Scientific Procedures) Act of 1986” published by Her Majesty’s
Stationary Office, London, United Kingdom. Rats were anesthe-
tized with 95% oxygen/5% carbon dioxide bubbled through di-
ethyl ether; they were then anticoagulated with intravenously
administered heparin (1000 IU/kg body weight).
Heart Isolation and Perfusion
Hearts were rapidly excised from the anesthetized rats and im-
mersed in cold (4°C) Krebs-Henseleit bicarbonate buffer (KHB).
The aorta was then cannulated, and the heart was perfused in the
Langendorff mode as previously described elsewhere.21 A unipolar
electrocardiogram was obtained through a silver electrode inserted
into the free wall of the left ventricle and a reference electrode
connected to the aortic cannula; the electrocardiogram was con-
tinuously recorded throughout the protocol. All hearts were sub-
jected to an equilibration period of aerobic perfusion for 20 min-
utes, and baseline readings of left ventricular systolic pressure (in
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millimeters of mercury), left ventricular end-diastolic pressure
(LVEDP; in millimeters of mercury), heart rate (in beats per
minute), and coronary flow (in milliliters per minute) were then
taken. Left ventricular developed pressure (LVDP) was calculated
as left ventricular systolic pressure minus LVEDP. Perfusion pres-
sure was monitored continuously through a sidearm of the aortic
cannula by means of a second pressure transducer. Coronary flow
was measured by timed collection of the coronary effluent. Infu-
sion volume of cardioplegic solution was measured by collecting
coronary effluent during infusion of cardioplegic solution.
Exclusion Criteria
Hearts not satisfying previously assigned inclusion criteria at the
time of the baseline readings (after 20 minutes of aerobic perfu-
sion) were excluded from the study. The acceptable ranges for
LVDP, heart rate, and coronary flow were greater than 100 mm
Hg, greater than 220 beats/min, and 8 to 16 mL/min, respectively.
Perfusion Medium
The perfusion medium was a modified KHB with the following
composition: 118.5-mmol/L sodium chloride, 25.0-mmol/L so-
Figure 1. For legend see opposite page.
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dium hydrogen carbonate, 4.8-mmol/L potassium chloride, 1.2-
mmol/L magnesium sulfate, 1.2-mmol/L potassium dihydrogen
orthophosphate, 1.4-mmol/L calcium chloride, and 11.0-mmol/L
glucose. The buffer was prepared daily and filtered through a 5-m
pore size cellulose nitrate membrane filter before use. Oxygenated
KHB (oxy-KHB) was continuously gassed with a 95% oxygen/5%
carbon dioxide mixture to yield a pH of 7.4 at 37°C. For deoxy-
genated KHB (deoxy-KHB), the buffer was continuously gassed
with a 95% nitrogen/5% carbon dioxide mixture so that a pH of 7.4
at 37°C was maintained.
Preparation and Administration of Esmolol and St
Thomas’ Hospital Cardioplegic Solutions
Esmolol (Brevibloc; Baxter Pharmaceuticals, Crowthorne, Berk-
shire, UK) was provided in vials containing 10 mL of a 250-
mg/mL solution. A 1.0-mmol/L esmolol solution (which we have
previously shown to be the optimal concentration to achieve car-
diac arrest20) was prepared by adding 1.5 mL of the concentrated
esmolol solution to 1000 mL of oxy-KHB. St Thomas’ Hospital
cardioplegic solution No. 2 (STH2) had the following composi-
tion: 110.0-mmol/L sodium chloride, 16.0-mmol/L magnesium
chloride hexahydrate, 16.0-mmol/L potassium chloride, 1.2-
mmol/L calcium chloride dihydrate, and 10.0-mmol/L sodium
hydrogen carbonate. STH2 was prepared daily, adjusted to pH 7.8
when at 37°C, and then filtered through a 5-m cellulose nitrate
membrane filter before use. These solutions were delivered at
37°C, either at constant pressure of 45 mm Hg or at a constant flow
rate of 14 mL/min for 3 minutes each infusion. Normothermic
(37°C) crystalloid cardioplegia was used in preference to hypo-
thermic crystalloid cardioplegia to avoid the additional protection
associated with hypothermia and thus measure the protective effect
of the cardioplegia itself.
Perfusion Protocol
In all perfusion protocols, each heart was supplied with KHB from
a temperature-regulated reservoir (37°C) at a constant perfusion
pressure equivalent to 75 mm Hg before and after global ischemia.
After equilibration, hearts were subjected to one of three perfusion
protocols, as shown in Figure 1. During the ischemic period, hearts
were immersed in KHB at 37°C (using a temperature-controlled,
water-jacketed heart chamber).
Study 1A: Effects on myocardial protection of oxygenation
during multidose infusion of esmolol cardioplegia. Hearts were
randomly assigned to one of four groups (n  6 per group): (i)
oxy-KHB, multidose oxy-KHB infused for 3 minutes at 14 mL/
min before and every 15 minutes during 60 minutes of intermittent
infusion and global ischemia; (ii) deoxy-KHB, multidose deoxy-
KHB infused for 3 minutes at 14 mL/min before and every 15
minutes during 60 minutes of intermittent infusion and global
ischemia; (iii) oxyesmolol, multidose oxygenated (95% oxy-
gen/5% carbon dioxide) esmolol infused for 3 minutes at 14
mL/min before and every 15 minutes during 60 minutes of inter-
mittent infusion and global ischemia; and (iv) deoxyesmolol, mul-
tidose deoxygenated (95% nitrogen/5% carbon dioxide) esmolol
infused for 3 minutes at 14 mL/min before and every 15 minutes
during 60 minutes of intermittent infusion and global ischemia. All
protocols were followed by a further 60 minutes of reperfusion,
Figure 1. Experimental perfusion protocols. In all protocols, hearts were perfused with KHB at constant pressure
equivalent to 75 mm Hg both before and after ischemia. Study 1A, Hearts were randomly assigned to one of four
groups (n  6 per group): oxy-KHB (i), multidose oxygenated (95% oxygen/5% carbon dioxide) KHB infused for 3
minutes at 14 mL/min before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia;
deoxy-KHB (ii), multidose deoxygenated (95% nitrogen/5% carbon dioxide) KHB infused for 3 minutes at 14 mL/min
before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia; oxyesmolol (iii),
multidose oxygenated (95% oxygen/5% carbon dioxide) esmolol infused for 3 minutes at 14 mL/min before and
every 15 minutes during 60 minutes of intermittent infusion and global ischemia; and deoxyesmolol (iv), multidose
deoxygenated (95% nitrogen/5% carbon dioxide) esmolol infused for 3 minutes at 14 mL/min before and every 15
minutes during 60 minutes of intermittent infusion and global ischemia. All protocols were followed by 60 further
minutes of reperfusion, when recovery of myocardial function was measured. Study 1B, Hearts were randomly
assigned to one of three groups (n  6 per group): STH2 (v), multidose normoxic (equilibrated with room air) STH2
infused for 3 minutes at 45 mm Hg before and every 15 minutes during 60 minutes of intermittent infusion and global
ischemia; oxy-STH2 (vi), multidose oxygenated (95% oxygen/5% carbon dioxide) STH2 infused for 3 minutes at 45
mm Hg before and every 15 minutes during 60 minutes of intermittent infusion and global ischemia; and oxyesmolol
(vii), multidose oxygenated (95% oxygen/5% carbon dioxide) esmolol infused for 3 minutes at 45 mm Hg before and
every 15 minutes during 60 minutes of intermittent infusion and global ischemia. All protocols were followed by
60 further minutes of reperfusion, when recovery of myocardial function was measured. Study 2, Hearts were
randomly assigned to one of four ischemic duration groups: 60, 75, 90, and 120 minutes of ischemia. In addition, for
each ischemic duration group, hearts were randomly assigned to four treatment groups (n  6 per group):
multidose KHB infused at constant flow (CF) for 3 minutes at 14 mL/min before and every 15 minutes during
intermittent infusion and global ischemia, multidose KHB infused at constant pressure (CP) for 3 minutes at 45 mm
Hg before and every 15 minutes during intermittent infusion and global ischemia, multidose esmolol cardioplegia
infused at constant flow for 3 minutes at 14 mL/min before and every 15 minutes during intermittent infusion and
global ischemia, and multidose esmolol cardioplegia infused at constant pressure for 3 minutes at 45 mm Hg before
and every 15 minutes during intermittent infusion and global ischemia. All protocols were followed by 60 further
minutes of reperfusion, when recovery of myocardial function was measured.
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when recovery of myocardial function was measured (Figure 1,
study 1A).
Study 1B: Comparison of myocardial protection by multidose
St Thomas’ Hospital cardioplegic solution No. 2 and esmolol
cardioplegia. Hearts were randomly assigned to one of three
groups (n  6 per group): (v) STH2, multidose normoxic (equil-
ibrated with room air) STH2 infused for 3 minutes at 45 mm Hg
before and every 15 minutes during 60 minutes of intermittent
infusion and global ischemia; (vi) oxy-STH2, multidose oxygen-
ated (95% oxygen/5% carbon dioxide) STH2 infused for 3 minutes
at 45 mm Hg before and every 15 minutes during 60 minutes of
intermittent infusion and global ischemia; and (vii) oxyesmolol,
multidose oxygenated (95% oxygen/5% carbon dioxide) esmolol
infused for 3 minutes at 45 mm Hg before and every 15 minutes
during 60 minutes of intermittent infusion and global ischemia. All
protocols were followed by a further 60 minutes of reperfusion,
when recovery of myocardial function was measured (Figure 1,
study 1B).
Study 2: Cardioprotective efficacy of multidose esmolol car-
dioplegia during prolonged ischemic durations. Hearts were ran-
domly assigned to one of four ischemic duration groups: 60, 75,
90, and 120 minutes of ischemia. In addition, within each ischemic
duration group, hearts were randomly assigned to four treatment
groups (n  6 per group): constant-flow KHB, multidose KHB
infused for 3 minutes at 14 mL/min before and every 15 minutes
during intermittent infusion and global ischemia; constant-pressure
KHB, multidose KHB infused for 3 minutes at 45 mm Hg before
and every 15 minutes during intermittent infusion and global
ischemia; constant-flow esmolol, multidose esmolol cardioplegia
infused for 3 minutes at 14 mL/min before and every 15 minutes
during intermittent infusion and global ischemia; and constant-
pressure esmolol, multidose esmolol cardioplegia infused for 3
minutes at 45 mm Hg before and every 15 minutes during inter-
mittent infusion and global ischemia. All protocols were followed
by a further 60 minutes of reperfusion, when recovery of myocar-
dial function was measured (Figure 1, study 2).
Expression of Results
Postischemic recoveries of LVDP, heart rate, and coronary flow
were expressed as percentage of baseline values at the end of 20
minutes of aerobic perfusion; LVEDP was expressed as an abso-
lute value (in millimeters of mercury). In addition, changes in
infusion pressure or infusion volume during drug infusion were
expressed as absolute values (in millimeters of mercury or milli-
liters per minute).
Statistical Analysis
Statistical analysis was performed with StatView and Super-
ANOVA (SAS Institute, Inc, Cary, NC) on an Apple Macintosh
computer (Apple Computer, Inc, Cupertino, Calif). All data are
reported as mean  SEM. Comparisons between groups were
assessed for significance by 1-way analysis of variance with post
hoc analysis with the Fisher protected least significant difference
test, which allowed multiple comparisons (or the Scheffe´ test when
appropriate). The Student paired t test was used to compare paired
means.
Results
Study 1A: Effects on Myocardial Protection of
Oxygenation During Multidose Infusion of Esmolol
Cardioplegia
The mean baseline values for LVDP, coronary flow, heart
rate, and LVEDP after 20 minutes of aerobic perfusion are
shown in Table 1. There were no significant differences
between groups in any of these values.
Recovery of function
LEFT VENTRICULAR DEVELOPED PRESSURE, CORONARY FLOW,
AND HEART RATE. The changes in recovery of LVDP during
60 minutes of reperfusion after 60 minutes of intermittent
global ischemia are shown in Figure 2, A. Hearts subjected
to multidose infusions of deoxy-KHB had almost no recov-
ery, whereas those subjected to oxy-KHB recovered rapidly
to a plateau value around 60% by 20 minutes. Addition of
1 mmol/L esmolol to either oxy-KHB or deoxy-KHB pro-
vided significant additional protection, improving recovery
by approximately 40% in either case (Figure 2, A, Table 1),
although the rate at which this was achieved was much
slower (reaching a plateau by 30 minutes) in the deoxyes-
molol group (Figure 2, A). Interestingly, oxygenation im-
proved recovery by approximately 50% in each case, indi-
cating the highly significant impact of oxygenation of these
solutions.
Recovery of coronary flow (after 60 minutes of intermit-
tent global ischemia) throughout 60 minutes of reperfusion
is shown in Figure 3, A. Similar values were observed in
both deoxygenated groups, reaching 60% by 5 minutes and
only increasing slowly to 70% to 80% by 60 minutes. In
contrast, both oxygenated groups exhibited a hyperemic
response (around 110% recovery) at 5 minutes, and this was
sustained in the oxyesmolol group but decreased in the
oxy-KHB group to similar levels as the deoxygenated
groups (Figure 3, A). Recovery of heart rate (Table 1) was
similar in all groups and hence did not appear to be related
to oxygenation.
LEFT VENTRICULAR END-DIASTOLIC PRESSURE. Essentially,
LVEDP recovery mirrored the results seen for LVDP; thus,
high values of LVEDP were maintained in the deoxygen-
ated groups, with lower values in the oxygenated groups.
The addition of esmolol to each solution was associated
with a beneficial decrease in LVEDP.
INFUSION PRESSURE OF CONSTANT-FLOW INFUSIONS DURING
ISCHEMIA. Infusion pressures at each of the four infusions
(before and every 15 minutes throughout ischemia) re-
mained relatively constant for the oxygenated solutions but
increased significantly with each infusion of the deoxygen-
ated solutions (Figure 4, A).
Study 1B: Comparison of Myocardial Protection by
Multidose STH2 and Esmolol Cardioplegia
The mean baseline values for LVDP, coronary flow, heart
rate, and LVEDP after 20 minutes of aerobic perfusion are
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shown in Table 2. There were no significant differences
between groups in any of these values.
Recovery of function
LEFT VENTRICULAR DEVELOPED PRESSURE, CORONARY FLOW,
AND HEART RATE. The recovery profiles of LVDP after 60
minutes of intermittent global ischemia (expressed as a
percentage of preischemic baseline value) are shown for
each group in Figure 2, B. Hearts from all groups recovered
rapidly and reached a plateau level within 5 to 20 minutes of
reperfusion. As before, hearts infused with multidose esmo-
lol cardioplegia recovered extremely rapidly to preischemic
values, which were significantly higher than the STH2
groups. Interestingly, there were no differences in recovery
between hearts subjected to oxy-STH2 and normoxic STH2.
Recovery of coronary flow during 60 minutes of reperfusion
after 60 minutes of intermittent global ischemia (Figure 3,
B) was similar to that in the previously described study
(study 1A). Thus recovery of coronary flow in hearts sub-
jected to multidose oxygenated esmolol was maintained at
values that were significantly higher (approximately 120%)
than preischemic baseline values (P  .05 vs preischemic
value). In contrast, hearts from both STH2 groups had
similar patterns of recovery, with coronary flow reaching a
hyperemic peak at 5 minutes of reperfusion followed by a
subsequent decline throughout the remaining reperfusion
period.
Recovery of heart rate (Table 2) was similar in all
groups, with no significant differences among all groups.
LEFT VENTRICULAR END-DIASTOLIC PRESSURE. Recovery of
LVEDP in all groups was similar to the corresponding
preischemic value. There were no differences between
groups throughout the reperfusion period.
INFUSION VOLUME OF CONSTANT PRESSURE-INFUSIONS DURING
ISCHEMIA. Infusion volume at each infusion (before and
every 15 minutes throughout ischemia) remained relatively
constant for both STH2 groups (Figure 4, B), although
oxy-STH2 group volumes were significantly higher than
those of STH2 and oxyesmolol groups. Interestingly, the
volume in the oxyesmolol group decreased significantly at
the second infusion but remained constant thereafter.
Study 2: Cardioprotective Efficacy of Multidose
Esmolol Cardioplegia During Prolonged Ischemic
Durations
We have shown that multiple infusions of oxygenated es-
molol cardioplegia completely protected hearts subjected to
45 minutes20 and 60 minutes (this study) of 37°C global
ischemia, regardless of the method of infusion (constant
flow or constant perfusion pressure). This study was there-
fore conducted to investigate the protective efficacy of
multidose esmolol cardioplegic infusions during prolonged
ischemia and also to determine whether the method of
infusion influences this protection.
The mean baseline values of LVDP ranged from 105.2
4.8 to 129.0  8.4 mm Hg in all groups; there were no
significant differences between groups. Similarly, coronary
flow ranged from 9.3 0.3 to 12.0 1.5 mL/min and heart
rate ranged from 253.7  12.0 to 283.5  7.2 beats/min,
with no significant differences between groups.
Recovery of function
LEFT VENTRICULAR DEVELOPED PRESSURE, CORONARY FLOW,
AND HEART RATE. Postischemic recovery of LVDP with in-
creasing duration of global ischemia is shown in Figure 5,
A. Hearts subjected to multidose esmolol cardioplegia in-
fused at constant pressure had complete recovery (approx-
imately 100% of preischemic values) for as long as 90
minutes of 37°C global ischemia and only decreased to
60.5%  4.9% after 120 minutes of 37°C global ischemia.
In hearts in which esmolol cardioplegia was infused at
constant flow, however, although recovery was 98.4% 
5.2% after 60 minutes of 37°C global ischemia (confirming
the results obtained in study 1A), recovery had decreased
dramatically to only 40.7%  4.3% by 75 minutes of 37°C
global ischemia. Surprisingly, further increases in ischemic
TABLE 1. Baseline values (measured after equilibration of 20 minutes aerobic perfusion) and percentage recovery (after
60 minutes of intermittent global ischemia and 60 minutes of reperfusion) of LVDP, coronary flow, heart rate, and LVEDP
Oxy-KHB Deoxy-KHB Oxyesmolol Deoxyesmolol
LVDP (mm Hg) 125 14 119 12 129 8 111 6
Recovery (%) 58.3 9.0* 4.4 1.5 97.2 4.7† 44.7 7.6*
Coronary flow (mL/min) 13.2 0.6 11.2 0.8 12.2 0.7 11.4 0.3
Recovery (%) 61.3 2.3 77.8 10.8 107.5 13.9‡ 66.6 5.1
Heart rate (beats/min) 273 7 269 12 245 7 265 8
Recovery (%) 95.6 2.9 104.9 5.6 107.4 7.2 88.5 3.9
LVEDP (mm Hg) 5.8 1.6 7.0 1.0 5.7 1.3 6.7 0.6
Final LVEDP (mm Hg) 29.8 8.4 72.3 4.1† 8.8 3.3† 42.7 4.4
The differences between groups in baseline values could be due to chance (P  .2).
*P  .05 versus deoxy-KHB.
†P  .01 versus other groups.
‡P  .05 versus other groups.
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duration (90 and 120 minutes) did not result in further
decreases (with recoveries of 39.2%  5.6% and 29.1% 
6.6%, respectively).
Recovery of hearts subjected to multidose KHB infusion,
either constant flow or constant pressure, decreased in a
linear fashion with increasing duration of ischemia. Myo-
cardial protection was significantly less than that with con-
stant-pressure esmolol cardioplegia but was similar to that
of constant-flow esmolol cardioplegia at all ischemic dura-
tions except 60 minutes.
Recovery of coronary flow in the esmolol cardioplegia–
treated hearts was similar to that of LVDP. Hearts treated
with KHB had a relatively constant recovery of coronary
flow of around 80% after all ischemic durations.
Surprisingly, the postischemic recovery of heart rate was
similar in all groups but tended to be slightly higher in the
KHB-treated hearts than in the esmolol cardioplegia–treated
hearts.
LEFT VENTRICULAR END-DIASTOLIC PRESSURE. Changes in
postischemic LVEDP (after 60 minutes of reperfusion) with
increasing ischemic durations are shown in Figure 5, B. In
Figure 2. Recovery of LVDP (expressed as percentage of preische-
mic control value) throughout 60 minutes of reperfusion. A, Study
1A. Filled diamonds represent oxy-KHB; open diamonds represent
deoxy-KHB; filled circles represent oxygenated esmolol (infused
at 14 mL/min); open circles represent deoxygenated esmolol. B,
Study 1B. Open triangles represent STH2; filled triangles repre-
sent oxy-STH2; filled squares represent oxygenated esmolol (in-
fused at 45 mm Hg). Data points represent mean; error bars
represent SEM; n  6 hearts/group. Pound sign indicates P < .01
versus all other groups.
Figure 3. Recovery of coronary flow (expressed as percentage of
preischemic control value) throughout 60 minutes of reperfusion.
A, Study 1A. Filled diamonds represent oxy-KHB; open diamonds
represent deoxy-KHB; filled circles represent oxygenated esmo-
lol (infused at 14 mL/min); open circles represent deoxygenated
esmolol. B, Study 1B. Open triangles represent STH2; filled trian-
gles represent oxy-STH2; filled squares represent oxygenated
esmolol (infused at 45 mm Hg). Data points represent mean; error
bars represent SEM; n  6 hearts/group. Asterisk indicates P <
.05 versus all other groups; pound sign indicates P < .01 versus
all other groups.
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each group, postischemic LVEDP increased with increasing
duration of ischemia. In hearts with constant-pressure es-
molol cardioplegia, LVEDP was significantly lower than in
other groups at 75 and 90 minutes of ischemia but had
increased to similar values by 120 minutes of ischemia. In
contrast, LVEDP increased dramatically between 60 and 75
minutes of ischemia in hearts with constant-flow esmolol
cardioplegia but then remained relatively constant.
INFUSION VOLUME OF CONSTANT-PRESSURE INFUSION DURING
ISCHEMIA. The infusion volumes at each infusion during
ischemia of either KHB or esmolol during constant-pressure
infusion are shown in Figure 6, A. Infusion volume de-
creased with each infusion in the hearts treated with esmolol
cardioplegia, whereas infusion volume changes in the KHB-
treated hearts were minimal.
INFUSION PRESSURE OF CONSTANT-FLOW INFUSIONS DURING
ISCHEMIA. The infusion pressures at each infusion during
ischemia of either KHB or esmolol during constant-flow
infusions are shown in Figure 6, B. KHB-treated hearts had
minimal changes in infusion pressure for each infusion; in
contrast, infusion pressure in the hearts treated with esmolol
cardioplegia increased at each infusion. This was particu-
larly evident between the fourth (60 minutes) and fifth (75
minutes) infusions, associated with a significant change in
postischemic recovery of LVDP (Figure 5, A).
Discussion
This study demonstrated that although oxygenation of an
esmolol-based arresting solution (esmolol cardioplegia) was
essential for complete myocardial protection, esmolol itself
exerted a significant protective effect. In addition, multidose
esmolol cardioplegia was also shown to provide myocardial
protection superior to that of STH2 under the same condi-
tions. Furthermore, recovery of hearts protected with mul-
tidose oxygenated esmolol cardioplegia infused at a con-
stant pressure during 37°C global ischemia remained at
approximately 100% of preischemic values for as long as 90
minutes.
Multidose, Oxygenated Infusions and Myocardial
Protection
Multidose infusion of hyperkalemic cardioplegia during
global ischemia improves myocardial protection relative to
TABLE 2. Baseline values (measured after equilibration of
20 minutes aerobic perfusion) and percentage recovery
(after 60 minutes of intermittent global ischemia and 60
minutes of reperfusion) of LVDP, coronary flow, heart rate,
and LVEDP
STH2 Oxy-STH2 Oxyesmolol
LVDP (mm Hg) 114 5 113 5 119 7
Recovery (%) 68.6 6.9 70.2 4.4 104.3 5.1*
Coronary flow (mL/min) 11.9 1.5 11.2 0.7 10.9 0.7
Recovery (%) 67.3 5.7 74.2 4.4 116.7 4.6*
Heart rate (beats/min) 269 10 262 11 260 5
Recovery (%) 104.9 3.9 102.6 3.8 94.8 4.8
LVEDP (mm Hg) 6.9 1.3 5.3 0.7 4.7 0.8
Final LVEDP (mm Hg) 7.8 3.7 6.2 1.1 11.0 1.8
The differences between groups in baseline values could be due to chance
(P  .2).
*P  .01 versus other groups.
Figure 4. Changes during global ischemia in infusion pressure at
each constant-flow infusion in study 1A (A) and infusion volume
at each constant-pressure infusion in study 1B (B). A, Study 1A.
Filled diamonds represent oxy-KHB; open diamonds represent
deoxy-KHB; filled circles represent oxygenated esmolol (infused
at 14 mL/min); open circles represent deoxygenated esmolol. B,
Study 1B. Open triangles represent STH2; filled triangles repre-
sent oxy-STH2; filled squares represent oxygenated esmolol (in-
fused at 45 mm Hg). Data points represent mean; error bars
represent SEM; n  6 hearts/group. Dagger indicates P < .05
versus oxy-KHB and oxyesmolol groups; double dagger indicates
P < .01 versus first infusion; pound sign indicates P < .05 versus
first infusion; asterisk indicates P < .05 versus all other groups.
Bessho and Chambers Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 2 347
CS
P
single-dose cardioplegia.22 Previously, we20 demonstrated
that multidose infusions of oxygenated esmolol cardioplegia
provided myocardial protection superior to that of a single
infusion; therefore, in this study, all cardioplegic solutions
were administered as multidose infusions. For normother-
mic ischemia, the initial cardioplegic infusion acts to arrest
contraction (conserving energy); cellular metabolic activity
will continue, however, and various anaerobic metabolites
such as lactate and protons will accumulate in the tissue.
Subsequent cardioplegic infusions remove toxic metabo-
lites, provide a small amount of oxygen for residual oxida-
tive metabolism, and (with some solutions) provide sub-
strates for anaerobic metabolism. In this study, the short
half-life (9 minutes) of esmolol means that its pharmaco-
logic effect will rapidly diminish, allowing the return of
contractile activity; periodic replenishment of this solution
would, therefore, be important to maintain diastolic arrest.
A potential disadvantage of multidose cardioplegia under
normothermic conditions might be the additional exposure
of the myocardium to calcium, sodium, and water, thereby
promoting tissue edema.
Clinically, intermittent ischemia (with or without fibril-
lation) and reperfusion continues to be used by some sur-
geons (particularly in the United Kingdom) with good
results,23,24 and we21 previously demonstrated that intermit-
tent global ischemia has an intrinsic myocardial protective
effect equivalent to that of a crystalloid cardioplegia
(STH2). That finding was confirmed by this study. Thus the
beneficial effect observed with multidose esmolol is likely
to be biphasic, involving both the protective effect of es-
molol and that of intermittent reperfusion, and this suppo-
sition was confirmed by the results from the deoxy-KHB
and deoxyesmolol groups in study 1A. Vascular washout
(by intermittent reperfusion) removes harmful metabolic
products (such as lactate, protons, or inorganic phosphate)
from the myocardium, reducing the cumulative effects of
these products during subsequent ischemia. In this study,
however, hearts treated with multidose infusion of deoxy-
KHB (intermittent washout of metabolites only) had a poor
recovery, suggesting that intermittent oxygenation rather
than intermittent washout was of primary benefit. Further-
more, esmolol added to deoxy-KHB enhanced myocardial
recovery to a value that was similar to that seen with
oxy-KHB, confirming the independent protective effect of
esmolol.
Most studies investigating the protective effect of oxy-
genation of crystalloid hyperkalemic cardioplegic solutions
have demonstrated beneficial effects on the myocardium,
both experimentally25,26 and clinically27; others, however,
have been unable to demonstrate these beneficial effects. In
this study (1B) we also failed to demonstrate an improve-
ment in recovery of function with oxygenated STH2 relative
to normoxic STH2; however, a number of differences be-
tween this and previous investigations may account for
these effects. In this study STH2 was gassed with 95%
oxygen/5% carbon dioxide (which maintained the pH at pH
7.0), as was esmolol cardioplegia (which had a pH of 7.4
with this gas mixture). In contrast, previous studies25,26,28
used 100% oxygen in STH2, which caused a significant
alkalosis and a depressed recovery of function. Although
STH2 is usually adjusted to pH 7.8 before use, experimental
Figure 5. Recovery of LVDP (A, expressed as percentage of
preischemic control value) and LVEDP (B) with increasing dura-
tions of global ischemia (study 2). Filled diamonds represent KHB
at constant flow; open inverted triangles represent KHB at con-
stant pressure; filled circles represent esmolol at constant flow;
and filled squares represent esmolol at constant pressure. Data
points represent mean; error bars represent SEM; n  6 hearts/
group. Double dagger indicates P < .01 versus KHB at constant
flow and KHB at constant pressure; asterisk indicates P < .01
versus all other groups; dagger indicates P < .05 versus all other
groups.
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studies29,30 have demonstrated that an alkaline pH may not
be optimal and that it should be used at neutral or slightly
acidic pH values for optimal efficacy. In addition, when
100% oxygen was used,25,26,28 STH2 and the ensuing ische-
mia were hypothermic (10°C-20°C); this ought to favor a
more alkaline pH,31 but it has been shown30 that STH2 only
changes by 0.05 of a pH unit across the range of 10°C to
40°C. Thus the pH values of the cardioplegic solutions used
in this study were closer to the optimum value, and this may
account for some of the differences between these studies
and others. It is also possible that increased myocardial
oxygen consumption at normothermia relative to delayed
consumption at hypothermia (with the improved mainte-
nance of high-energy phosphate compounds) may have
influenced these differing results.
In contrast, it is obvious that oxygenation of esmolol
cardioplegia plays an important role in its myocardial pro-
tection. Multidose infusion (every 15 minutes) of oxygen-
ated esmolol (oxy-KHB containing 1 mmol/L esmolol)
completely protected hearts during 60 minutes of 37°C
global ischemia, whereas deoxygenated esmolol (gassed
with 95% nitrogen/5% carbon dioxide) was significantly
less protective. However, deoxy-KHB gave almost no pro-
tection, indicating a significant protective effect for esmolol
per se. It is possible that esmolol, by reducing myocardial
oxygen demand, delays injury to the ischemic myocardium,
and that reperfusion (reinfusion) with oxygenated esmolol
cardioplegia at a time when the protected myocardium is
still reversibly damaged may attenuate ischemic injury. If,
on the other hand, reperfusion is initiated too late or anoxia
continues, the myocardium is irreversibly injured, and es-
molol fails to protect fully. Interestingly, Toleikis and Tom-
linson32 also demonstrated that acute -blockade, both be-
fore and during a relatively short (30-minute) period of
normothermic low-flow global ischemia in isolated rabbit
hearts, was protective, whereas similar treatment through 60
minutes of ischemia was ineffective, supporting our sugges-
tion that -blockers are only likely to be protective during
short periods of ischemia. Thus intermittent aerobic reper-
fusion may be required for esmolol cardioplegia to provide
full myocardial protection.
Method of Infusion: Constant Flow Versus Constant
Pressure
The direct vascular effects of esmolol were examined by
Gorczynski13 in constant-flow–perfused hind limbs of pen-
tobarbital-anesthetized, ganglion-blocked dogs. That study
indicated that esmolol is devoid of direct vascular effects at
doses that are within or above the -blocking range but that
extremely large doses may cause vasoconstriction. Murthy
and Frishman33 showed that intravenous infusion of esmolol
increased both mean coronary resistance and diastolic cor-
onary resistance in dogs under barbiturate anesthesia. Our
study confirmed these findings when esmolol cardioplegia
was infused at constant flow and perfusion pressure was
monitored (Figure 6, B). Infusion pressure increased signif-
icantly at the fifth infusion and was closely correlated with
a significant decrease in recovery of LVDP (Figure 5, A)
and increased LVEDP (Figure 5, B); hence, this increased
infusion pressure (coronary vascular resistance) appeared to
be a cause of myocardial injury. Similarly, increasing num-
bers of infusions of esmolol cardioplegia at constant pres-
sure resulted in a decline in infusion volume (reflecting the
vasoconstrictive action of esmolol13 and associated with a
considerably larger increase in coronary vascular resistance
[data not shown] in both study 2 and study 1A), but that was
not associated with a depressed recovery of function.
The lower coronary vascular resistance observed in con-
stant-flow–infused hearts may be an artificial consequence
of the infusion being forced through the vasculature (caus-
Figure 6. Changes during global ischemia in study 2 in infusion
volume at each constant-pressure infusion (A) and infusion pres-
sure at each constant-flow infusion (B). Open circles represent
KHB; filled circles represent esmolol. Data points represent
mean; error bars represent SEM; n  at least 6 hearts/group.
Asterisk indicates P < .05 versus esmolol in A, and P < .001
versus KHB in B.
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ing vascular injury) and may lead to increased tissue edema,
which would lead to deterioration in postischemic function.
Although myocardial edema was not measured in this study,
constant-pressure esmolol perfusion has previously been
shown16 to minimize myocardial edema. We observed sig-
nificantly lower LVEDP levels in hearts infused with esmo-
lol cardioplegia at constant pressure (Figure 5, B), which
would tend to support this suggestion.
Possible Protective Mechanisms of Esmolol
In this study, hearts infused (3 minutes every 15 minutes at
constant pressure of 45 mm Hg) with oxygenated esmolol
cardioplegia were completely protected for as long as 90
minutes of 37°C global ischemia. It is intriguing to specu-
late on how this could be achieved.
Initiation of ischemic arrest is associated with an accel-
erated release of endogenous catecholamines, producing a
period of hypermetabolic function.34 This results in deple-
tion of intracellular high-energy phosphate stores, which
sharply reduces the tolerance of the cell to ischemia.32 The
best available technique to maintain this tolerance involves
reducing cell metabolism, thereby avoiding the period of
hypermetabolic function and reducing the oxygen demands
of the cell. We have previously shown20 that esmolol car-
dioplegia induces a rapid arrest (at a mean duration of
around 50 seconds), which is similar to that of St Thomas’
Hospital cardioplegia (around 35 seconds) and significantly
shorter than ischemia alone (around 220 seconds). It is
likely that part of the protective mechanism of esmolol
cardioplegia involves maintenance of high-energy phos-
phates by rapid reduction of energy demands. -Blockers,
administered either before or just after ischemia, have been
shown in numerous animal models1-4 to exert beneficial
effects on ischemic myocardium. Although the mechanism
for these benefits are unknown, speculations include im-
proved balance between oxygen supply and demand by
reducing oxygen demand through negative inotropic and
chronotropic actions,5,35 increased oxygen supply as a result
of increased blood flow to ischemic areas,35 and redistribu-
tion of blood flow from the subepicardium to the subendo-
cardium.36 We also observed that hearts treated with oxy-
genated esmolol had a significantly higher coronary flow,
which was sustained throughout the reperfusion period.
This elevated coronary flow would considerably increase
the available oxygen supply to the previously ischemic
myocardium and thus represents a potential additional
mechanism by which esmolol exerted its protective effect in
this study. Thus multidose infusions of oxygenated esmolol
cardioplegia may combine the protection that we previously
observed with intermittent global ischemia and reperfu-
sion21 with that of rapid cardiac arrest (which decreases
myocardial oxygen consumption), thereby enhancing over-
all protection.
Limitations of This Study
We concede that these studies were conducted in rat hearts
perfused with a crystalloid solution rather than blood and
that this is a relatively unphysiologic situation. We are
aware that esmolol is metabolized by blood esterases12;
consequently, this study would fail to reveal any interaction
between the metabolism of esmolol and the cardioprotective
efficacy of esmolol. It would be important to establish
whether blood-based esmolol cardioplegia would be as ef-
fective as the crystalloid solutions used in these studies, and
further studies are warranted.
It is also possible that esmolol may have adverse sys-
temic effects that would not be revealed in our study; this
would require investigation in the intact animal. Previous
studies14,16,17 have used esmolol clinically during relatively
long-term continuous infusions (albeit at lower concentra-
tions), with no reports of any systemic adverse effects.
Hence, we speculate that multiple, short, high-dose infu-
sions are unlikely to have major systemic effects, although
this would need verification.
Myocardial ischemic disease is a multifactorial process;
there is a spectrum of injury that affects the method of
myocardial protection. Hearts used in this study were taken
from healthy rats, and it is likely that any protective effect
of esmolol would be different in jeopardized hearts suffer-
ing from ischemic injury or disease. In addition, any such
hearts are likely to require prolonged periods of ischemia to
correct the lesion, and we have shown that multidose es-
molol infusions are effective for relatively prolonged isch-
emic durations at 37°C.
Although it is dangerous to extrapolate from experimen-
tal studies in the isolated rat heart to the clinical situation,
there are a number of potential clinical benefits that might
be available with the use of esmolol cardioplegia. The total
volume of esmolol required to induce and maintain cardiac
arrest is quite low (the addition of a suitable volume of
esmolol to oxygenated blood to make up a 1 mmol/L
concentration) relative to potassium cardioplegia, for which
volumes in excess of 1000 mL are required. Consequently,
additional hemodilution during cardiopulmonary bypass
should be avoided with esmolol arrest, in contrast to warm
continuous-infusion of blood cardioplegia or the cardiac
surgical condition induced with esmolol added to blood for
continuous infusion,14-16 multidose intermittent esmolol in-
fusion would provide a still and blood-free operating field
during warm (normothermic) heart surgery. This technique
of multidose esmolol infusion can be used for coronary
artery bypass surgery, or any other type of cardiac surgery.
Conclusion
Oxygenation of the esmolol cardioplegia was essential for
optimal myocardial protection, and it was shown to be more
efficacious than the well-established STH2. Moreover, mul-
tidose infusions of oxygenated esmolol cardioplegia main-
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tained complete protection for normothermic ischemic pe-
riods as long as 90 minutes. Esmolol cardioplegia thus may
provide on efficacious alternative to hyperkalemia.
Dr Ryuzo Bessho was a visiting research fellow from the
Division of Cardiovascular Surgery, the Department of Surgery II,
Nippon Medical School, Tokyo, Japan.
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